Although anti-VEGF agents have reduced the rates of blindness from nAMD worldwide [5, 6] and will likely have a similar impact on blindness owing to DMO/diabetic retinopathy (DR) [7], these diseases continue to be leading causes of visual impairment [8] and the resultant societal costs remain high [9]. The gene discussed is VEGFA; the disease is blindness (disorder).